Lung Cancer Treatments for MET Alterations

There are several different options for lung cancer treatments with MET alterations available in clinical trials. In some cases of lung cancer, specifically non-small cell lung cancer, MET gene amplification can cause the cancerous cells to reproduce and spread more quickly than lung cancer cases without known biomarkers. Those who test positive for a MET amplification may respond better to a MET targeted therapy.MET Crusaders Cancer Patient and Caregiver Support Group released the Q1 2021 research edition of the crusader newsletter is a free resource including information on the latest therapies for NSCLC and MET cancer. The newsletter lists and reviews clinical trial therapies such as:

• Crizotinib
• Cabozantinib
• Capmatinib
• Gefitinib
• Immune checkpoint inhibitors
• Anti-PD-1 Immunotherapy

MET Crusaders Cancer Patient and Caregiver Support Group was founded in 2019 by MET lung cancer survivor John Hallick to help others with MET altered cancer and wanted to promote treatment options. Today, MET Crusaders is a community dedicated to helping lung cancer patients with MET alterations live normal lives. You can download and read the full Crusader Newsletter below.

Download the Crusader Newsletter

MET Alteration and Lung Cancer Research

Clinical trials develop and evaluate the effectiveness of cancer treatments including lung cancer with MET alterations. Before being approved by the FDA, clinical trials go through several phases to ensure the safety and effectiveness of the drug. The crusader newsletter reviews these therapies and results from the ongoing clinical trials. For each article in the newsletter, the following categories are used to summarize and evaluate the different treatments and clinical trials for MET alterations:

• Objective of the study
• Design of the clinical trial
• Population of the trial
• Effectiveness result of the therapy or drug
• Safety results of the trial
• Strengths and weaknesses of the therapy
• Conclusion to summarize the study

There are over 60 lung cancer MET-amplified clinical trials available to eligible patients. Download and read the full newsletter for more on clinical trials and therapies targeting MET alterations in lung cancer. There is also more information about these trials and lung cancer with MET alterations on the MET Crusaders website and Facebook group.